Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 421


Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer.

Hong DS, Concin N, Vergote I, de Bono JS, Slomovitz BM, Drew Y, Arkenau HT, Machiels JP, Spicer J, Jones R, Forster M, Cornez N, Gennigens C, Johnson ML, Thistlethwaite FC, Rangwala RA, Ghatta S, Windfeld K, Harris JR, Lassen UN, Coleman RL.

Clin Cancer Res. 2019 Dec 3. pii: clincanres.2962.2019. doi: 10.1158/1078-0432.CCR-19-2962. [Epub ahead of print]


Discrepancy in calculated and measured glomerular filtration rates in patients treated with PARP inhibitors.

Zibetti Dal Molin G, Westin SN, Msaouel P, Gomes LM, Dickens A, Coleman RL.

Int J Gynecol Cancer. 2019 Dec 1. pii: ijgc-2019-000714. doi: 10.1136/ijgc-2019-000714. [Epub ahead of print]


Tumor core biopsies adequately represent immune microenvironment of high-grade serous carcinoma.

Lara OD, Krishnan S, Wang Z, Corvigno S, Zhong Y, Lyons Y, Dood R, Hu W, Qi L, Liu J, Coleman RL, Westin SN, Fleming ND, Cristini V, Rao A, Burks J, Sood AK.

Sci Rep. 2019 Nov 26;9(1):17589. doi: 10.1038/s41598-019-53872-1.


Emerging serine-threonine kinase inhibitors for treating ovarian cancer.

Maoz A, Ciccone MA, Matsuzaki S, Coleman RL, Matsuo K.

Expert Opin Emerg Drugs. 2019 Nov 22. doi: 10.1080/14728214.2019.1696773. [Epub ahead of print]


Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer.

Coleman RL, Spirtos NM, Enserro D, Herzog TJ, Sabbatini P, Armstrong DK, Kim JW, Park SY, Kim BG, Nam JH, Fujiwara K, Walker JL, Casey AC, Alvarez Secord A, Rubin S, Chan JK, DiSilvestro P, Davidson SA, Cohn DE, Tewari KS, Basen-Engquist K, Huang HQ, Brady MF, Mannel RS.

N Engl J Med. 2019 Nov 14;381(20):1929-1939. doi: 10.1056/NEJMoa1902626.


Phase II, 2-Stage, 2-Arm, PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent Endometrial Cancer.

Myers AP, Konstantinopoulos PA, Barry WT, Luo W, Broaddus RR, Makker V, Drapkin R, Liu J, Doyle A, Horowitz NS, Meric-Bernstam F, Birrer M, Aghajanian C, Coleman RL, Mills GB, Cantley LC, Matulonis UA, Westin SN.

Int J Cancer. 2019 Nov 12. doi: 10.1002/ijc.32783. [Epub ahead of print]


Clinical and biological significance of EZH2 expression in endometrial cancer.

Roh JW, Choi JE, Han HD, Hu W, Matsuo K, Nishimura M, Lee JS, Kwon SY, Cho CH, Kim J, Coleman RL, Lopez-Bernstein G, Sood AK.

Cancer Biol Ther. 2019 Oct 22:1-10. doi: 10.1080/15384047.2019.1672455. [Epub ahead of print]


Everolimus, letrozole, and metformin in women with advanced or recurrent endometrioid endometrial cancer: A multi-center, single arm, phase II study.

Soliman PT, Westin SN, Iglesias DA, Fellman BM, Ying Y, Zhang Q, Yates MS, Broaddus RR, Slomovitz BM, Lu KH, Coleman RL.

Clin Cancer Res. 2019 Oct 18. pii: clincanres.0471.2019. doi: 10.1158/1078-0432.CCR-19-0471. [Epub ahead of print]


Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study.

Westin SN, Sill MW, Coleman RL, Waggoner S, Moore KN, Mathews CA, Martin LP, Modesitt SC, Lee S, Ju Z, Mills GB, Schilder RJ, Fracasso PM, Birrer MJ, Aghajanian C.

Gynecol Oncol. 2019 Dec;155(3):420-428. doi: 10.1016/j.ygyno.2019.09.024. Epub 2019 Oct 15.


Meta-analysis of the impact of alpha-glucosidase inhibitors on incident diabetes and cardiovascular outcomes.

Coleman RL, Scott CAB, Lang Z, Bethel MA, Tuomilehto J, Holman RR.

Cardiovasc Diabetol. 2019 Oct 17;18(1):135. doi: 10.1186/s12933-019-0933-y.


Correction: Heterotypic CAF-tumor spheroids promote early peritoneal metastatis of ovarian cancer.

Gao Q, Yang Z, Xu S, Li X, Yang X, Jin P, Liu Y, Zhou X, Zhang T, Gong C, Wei X, Liu D, Sun C, Chen G, Hu J, Meng L, Zhou J, Sawada K, Fruscio R, Grunt TW, Wischhusen J, Vargas-Hernández VM, Pothuri B, Coleman RL.

J Exp Med. 2019 Oct 7;216(10):2448. doi: 10.1084/jem.2018076508222019c. No abstract available.


Incidence of adverse events in minimally invasive versus open radical hysterectomy in early cervical cancer: Results of a randomized controlled trial.

Obermair A, Asher R, Pareja R, Frumovitz M, Lopez A, Moretti-Marques R, Rendon G, Ribeiro R, Tsunoda A, Behan V, Buda A, Bernadini MQ, Zhao H, Vieira M, Walker J, Spirtos NM, Yao S, Chetty N, Zhu T, Isla D, Tamura M, Nicklin J, Robledo KP, Gebski V, Coleman RL, Salvo G, Ramirez PT.

Am J Obstet Gynecol. 2019 Oct 3. pii: S0002-9378(19)31165-2. doi: 10.1016/j.ajog.2019.09.036. [Epub ahead of print]


Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.

Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M, Okamoto A, Moore KN, Efrat Ben-Baruch N, Werner TL, Cloven NG, Oaknin A, DiSilvestro PA, Morgan MA, Nam JH, Leath CA 3rd, Nicum S, Hagemann AR, Littell RD, Cella D, Baron-Hay S, Garcia-Donas J, Mizuno M, Bell-McGuinn K, Sullivan DM, Bach BA, Bhattacharya S, Ratajczak CK, Ansell PJ, Dinh MH, Aghajanian C, Bookman MA.

N Engl J Med. 2019 Sep 28. doi: 10.1056/NEJMoa1909707. [Epub ahead of print]


Correction: Heterotypic CAF-tumor spheroids promote early peritoneal metastatis of ovarian cancer.

Gao Q, Yang Z, Xu S, Li X, Yang X, Jin P, Liu Y, Zhou X, Zhang T, Gong C, Wei X, Liu D, Sun C, Chen G, Hu J, Meng L, Zhou J, Sawada K, Fruscio R, Grunt TW, Wischhusen J, Vargas-Hernández VM, Pothuri B, Coleman RL.

J Exp Med. 2019 Aug 27. pii: jem.2018076508222019C. doi: 10.1084/jem.2018076508222019C. [Epub ahead of print] No abstract available.


OVQUEST - Life after the diagnosis and treatment of ovarian cancer - An international survey of symptoms and concerns in ovarian cancer survivors.

Webber K, Carolus E, Mileshkin L, Sommeijer D, McAlpine J, Bladgen S, Coleman RL, Herzog TJ, Sehouli J, Nasser S, Inci G, Friedlander M.

Gynecol Oncol. 2019 Oct;155(1):126-134. doi: 10.1016/j.ygyno.2019.08.009. Epub 2019 Aug 13.


Anti-Angiogenesis Therapy in Ovarian Cancer: Which Patient is It Most Likely to Benefit?

Chelariu-Raicu A, Coleman RL, Sood AK.

Oncology (Williston Park). 2019 Jul 16;33(7). pii: 629378.


Prospective pilot trial with combination of propranolol with chemotherapy in patients with epithelial ovarian cancer and evaluation on circulating immune cell gene expression.

Ramondetta LM, Hu W, Thaker PH, Urbauer DL, Chisholm GB, Westin SN, Sun Y, Ramirez PT, Fleming N, Sahai SK, Nick AM, Arevalo JMG, Dizon T, Coleman RL, Cole SW, Sood AK.

Gynecol Oncol. 2019 Sep;154(3):524-530. doi: 10.1016/j.ygyno.2019.07.004. Epub 2019 Jul 25.


Joint ENGOT and GOG Foundation requirements for trials with industry partners.

Vergote I, Coleman RL, Pignata S, Bookman MA, Marth C, Herzog TJ, Gonzalez-Martin A, Copeland LJ; European Network of Gynaecological Oncological Trial Groups (ENGOT); GOG Foundation Inc.

Gynecol Oncol. 2019 Aug;154(2):255-258. doi: 10.1016/j.ygyno.2019.04.677. No abstract available.


Joint ENGOT and GOG Foundation requirements for trials with industry partners.

Vergote I, Coleman RL, Pignata S, Bookman MA, Marth C, Herzog TJ, Gonzalez Martin A, Copeland LJ; European Network of Gynaecological Oncological Trial Groups (ENGOT) and The GOG Foundation, Inc.

Int J Gynecol Cancer. 2019 Sep;29(7):1094-1097. doi: 10.1136/ijgc-2019-000441. Epub 2019 Jul 18. No abstract available.


Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer.

Tewari KS, Burger RA, Enserro D, Norquist BM, Swisher EM, Brady MF, Bookman MA, Fleming GF, Huang H, Homesley HD, Fowler JM, Greer BE, Boente M, Liang SX, Ye C, Bais C, Randall LM, Chan JK, Ferriss JS, Coleman RL, Aghajanian C, Herzog TJ, DiSaia PJ, Copeland LJ, Mannel RS, Birrer MJ, Monk BJ.

J Clin Oncol. 2019 Sep 10;37(26):2317-2328. doi: 10.1200/JCO.19.01009. Epub 2019 Jun 19.


Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options.

Labrie M, Kim TB, Ju Z, Lee S, Zhao W, Fang Y, Lu Y, Chen K, Ramirez P, Frumovitz M, Meyer L, Fleming ND, Sood AK, Coleman RL, Mills GB, Westin SN.

Oncotarget. 2019 May 28;10(37):3533-3546. doi: 10.18632/oncotarget.26947. eCollection 2019 May 28.


Advancing Drug Development in Gynecologic Malignancies.

Beaver JA, Coleman RL, Arend RC, Armstrong DK, Bala S, Mills GB, Sood AK, Herzog TJ.

Clin Cancer Res. 2019 Aug 15;25(16):4874-4880. doi: 10.1158/1078-0432.CCR-19-0619. Epub 2019 May 24.


Poly-ADP-ribose polymerase inhibitor use in ovarian cancer: expanding indications and novel combination strategies.

Hinchcliff E, Westin SN, Dal Molin G, LaFargue CJ, Coleman RL.

Int J Gynecol Cancer. 2019 May 22. pii: ijgc-2019-000499. doi: 10.1136/ijgc-2019-000499. [Epub ahead of print]


Identifying markers of immune response in ovarian cancer: does PD-L1 expression meet the mark?

Gaillard SL, Coleman RL.

Ann Oncol. 2019 Jul 1;30(7):1025-1028. doi: 10.1093/annonc/mdz166. No abstract available.


Long-term risk of cardiovascular disease in individuals with latent autoimmune diabetes in adults (UKPDS 85).

Maddaloni E, Coleman RL, Pozzilli P, Holman RR.

Diabetes Obes Metab. 2019 Sep;21(9):2115-2122. doi: 10.1111/dom.13788. Epub 2019 Jun 19.


Correction: Focal Adhesion Kinase Targeting Using In vivo Short Interfering RNA Delivery in Neutral Liposomes for Ovarian Carcinoma Therapy.

Halder J, Kamat AA, Landen CN Jr, Han LY, Lutgendorf SK, Lin YG, Merritt WM, Jennings NB, Chavez-Reyes A, Coleman RL, Gershenson DM, Schmandt R, Cole SW, Lopez-Berestein G, Sood AK.

Clin Cancer Res. 2019 May 15;25(10):3194. doi: 10.1158/1078-0432.CCR-19-1132. No abstract available.


Paclitaxel and Alisertib in Recurrent Ovarian Cancer-In Reply.

Falchook G, Coleman RL, Schilder RJ.

JAMA Oncol. 2019 Jun 1;5(6):910-911. doi: 10.1001/jamaoncol.2019.0562. No abstract available.


GnRH-R-Targeted Lytic Peptide Sensitizes BRCA Wild-type Ovarian Cancer to PARP Inhibition.

Ma S, Pradeep S, Villar-Prados A, Wen Y, Bayraktar E, Mangala LS, Kim MS, Wu SY, Hu W, Rodriguez-Aguayo C, Leuschner C, Liang X, Ram PT, Schlacher K, Coleman RL, Sood AK.

Mol Cancer Ther. 2019 May;18(5):969-979. doi: 10.1158/1535-7163.MCT-18-0770. Epub 2019 Mar 29.


TOP: Time-to-Event Bayesian Optimal Phase II Trial Design for Cancer Immunotherapy.

Lin R, Coleman RL, Yuan Y.

J Natl Cancer Inst. 2019 Mar 29. pii: djz049. doi: 10.1093/jnci/djz049. [Epub ahead of print]


Microsatellite instability in endometrial cancer: New purpose for an old test.

Kurnit KC, Westin SN, Coleman RL.

Cancer. 2019 Mar 26. doi: 10.1002/cncr.32058. [Epub ahead of print] No abstract available.


Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option.

Buechel M, Herzog TJ, Westin SN, Coleman RL, Monk BJ, Moore KN.

Ann Oncol. 2019 May 1;30(5):721-732. doi: 10.1093/annonc/mdz104.


Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.

Konstantinopoulos PA, Barry WT, Birrer M, Westin SN, Cadoo KA, Shapiro GI, Mayer EL, O'Cearbhaill RE, Coleman RL, Kochupurakkal B, Whalen C, Curtis J, Farooq S, Luo W, Eismann J, Buss MK, Aghajanian C, Mills GB, Palakurthi S, Kirschmeier P, Liu J, Cantley LC, Kaufmann SH, Swisher EM, D'Andrea AD, Winer E, Wulf GM, Matulonis UA.

Lancet Oncol. 2019 Apr;20(4):570-580. doi: 10.1016/S1470-2045(18)30905-7. Epub 2019 Mar 14.


Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference.

Bast RC Jr, Matulonis UA, Sood AK, Ahmed AA, Amobi AE, Balkwill FR, Wielgos-Bonvallet M, Bowtell DDL, Brenton JD, Brugge JS, Coleman RL, Draetta GF, Doberstein K, Drapkin RI, Eckert MA, Edwards RP, Elias KM, Ennis D, Futreal A, Gershenson DM, Greenberg RA, Huntsman DG, Ji JXY, Kohn EC, Iavarone C, Lengyel ER, Levine DA, Lord CJ, Lu Z, Mills GB, Modugno F, Nelson BH, Odunsi K, Pilsworth JA, Rottapel RK, Powell DJ Jr, Shen L, Shih IM, Spriggs DR, Walton J, Zhang K, Zhang R, Zou L.

Cancer. 2019 Jun 15;125(12):1963-1972. doi: 10.1002/cncr.32004. Epub 2019 Mar 5.


Phase III trials in ovarian cancer: The evolving landscape of front line therapy.

Naumann RW, Coleman RL, Brown J, Moore KN.

Gynecol Oncol. 2019 May;153(2):436-444. doi: 10.1016/j.ygyno.2019.02.008. Epub 2019 Feb 12. Review.


Heterotypic CAF-tumor spheroids promote early peritoneal metastatis of ovarian cancer.

Gao Q, Yang Z, Xu S, Li X, Yang X, Jin P, Liu Y, Zhou X, Zhang T, Gong C, Wei X, Liu D, Sun C, Chen G, Hu J, Meng L, Zhou J, Sawada K, Fruscio R, Grunt TW, Wischhusen J, Vargas-Hernández VM, Pothuri B, Coleman RL.

J Exp Med. 2019 Mar 4;216(3):688-703. doi: 10.1084/jem.20180765. Epub 2019 Feb 1. Erratum in: J Exp Med. 2019 Aug 27;:. J Exp Med. 2019 Oct 7;216(10):2448.


Presumed early ovarian cancer with isolated tumor cells in para-aortic sentinel nodes.

Uccella S, Fagotti A, Zannoni GF, Coleman RL.

Int J Gynecol Cancer. 2019 Jan;29(1):216-220. doi: 10.1136/ijgc-2018-000005. No abstract available.


Exploring and comparing adverse events between PARP inhibitors.

LaFargue CJ, Dal Molin GZ, Sood AK, Coleman RL.

Lancet Oncol. 2019 Jan;20(1):e15-e28. doi: 10.1016/S1470-2045(18)30786-1. Review.


Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer.

Kurnit KC, Coleman RL, Westin SN.

Curr Treat Options Oncol. 2018 Nov 15;19(12):1. doi: 10.1007/s11864-018-0572-7. Review.


A randomized phase II study of letrozole vs. observation in patients with newly diagnosed uterine leiomyosarcoma (uLMS).

Slomovitz BM, Taub MC, Huang M, Levenback C, Coleman RL.

Gynecol Oncol Rep. 2018 Nov 16;27:1-4. doi: 10.1016/j.gore.2018.11.001. eCollection 2019 Feb.


BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.

Lin KK, Harrell MI, Oza AM, Oaknin A, Ray-Coquard I, Tinker AV, Helman E, Radke MR, Say C, Vo LT, Mann E, Isaacson JD, Maloney L, O'Malley DM, Chambers SK, Kaufmann SH, Scott CL, Konecny GE, Coleman RL, Sun JX, Giordano H, Brenton JD, Harding TC, McNeish IA, Swisher EM.

Cancer Discov. 2019 Feb;9(2):210-219. doi: 10.1158/2159-8290.CD-18-0715. Epub 2018 Nov 13.


Management and Treatment of Recurrent Epithelial Ovarian Cancer.

Armbruster S, Coleman RL, Rauh-Hain JA.

Hematol Oncol Clin North Am. 2018 Dec;32(6):965-982. doi: 10.1016/j.hoc.2018.07.005. Review.


Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer.

Ramirez PT, Frumovitz M, Pareja R, Lopez A, Vieira M, Ribeiro R, Buda A, Yan X, Shuzhong Y, Chetty N, Isla D, Tamura M, Zhu T, Robledo KP, Gebski V, Asher R, Behan V, Nicklin JL, Coleman RL, Obermair A.

N Engl J Med. 2018 Nov 15;379(20):1895-1904. doi: 10.1056/NEJMoa1806395. Epub 2018 Oct 31.


Concordance of a laparoscopic scoring algorithm with primary surgery findings in advanced stage ovarian cancer.

Hansen JM, Sood AK, Coleman RL, Westin SN, Soliman PT, Ramirez PT, Fellman BM, Schmeler KM, Fleming ND.

Gynecol Oncol. 2018 Dec;151(3):428-432. doi: 10.1016/j.ygyno.2018.10.017. Epub 2018 Oct 23.


Simulating the impact of targeting lower systolic blood pressure and LDL-cholesterol levels on type 2 diabetes complication rates.

Mostafa SA, Coleman RL, Agbaje OF, Gray AM, Holman RR, Bethel MA.

J Diabetes Complications. 2019 Jan;33(1):69-74. doi: 10.1016/j.jdiacomp.2018.09.017. Epub 2018 Oct 10.


Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial.

Falchook G, Coleman RL, Roszak A, Behbakht K, Matulonis U, Ray-Coquard I, Sawrycki P, Duska LR, Tew W, Ghamande S, Lesoin A, Schwartz PE, Buscema J, Fabbro M, Lortholary A, Goff B, Kurzrock R, Martin LP, Gray HJ, Fu S, Sheldon-Waniga E, Lin HM, Venkatakrishnan K, Zhou X, Leonard EJ, Schilder RJ.

JAMA Oncol. 2019 Jan 1;5(1):e183773. doi: 10.1001/jamaoncol.2018.3773. Epub 2019 Jan 10.


A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice.

Jazaeri A, Coleman RL, Sood AK, Frumovitz MM, Soliman PT, Shafer A, Cutrera JJ, Klinger M, Sharafi SE, Johnson CAL, Villanueva VF, Hinchcliff EM, Dickens A, Cain KE, Anderson JE, Lu KH, Westin SN.

Gynecol Oncol. 2018 Nov;151(2):374-380. doi: 10.1016/j.ygyno.2018.08.037. Epub 2018 Sep 10. Review.


Race and nodal disease status are prognostic factors in patients with stage IVB cervical cancer.

Nishio S, Matsuo K, Yonemoto K, Shimokawa M, Hosaka M, Kodama M, Miyake TM, Ushijima K, Kamura T, Westin SN, Soliman PT, Coleman RL.

Oncotarget. 2018 Aug 17;9(64):32321-32330. doi: 10.18632/oncotarget.25962. eCollection 2018 Aug 17.


Response to pembrolizumab in a heavily treated patient with metastatic ovarian carcinosarcoma.

Zibetti Dal Molin G, Abrahão CM, Coleman RL, Maluf FC.

Gynecol Oncol Res Pract. 2018 Aug 18;5:6. doi: 10.1186/s40661-018-0063-3. eCollection 2018.


Rucaparib in ovarian cancer: extending the use of PARP inhibitors in the recurrent disease.

Dal Molin GZ, Westin SN, Coleman RL.

Future Oncol. 2018 Dec;14(30):3101-3110. doi: 10.2217/fon-2018-0215. Epub 2018 Aug 14. Review.


Laparoscopic Surgical Algorithm to Triage the Timing of Tumor Reductive Surgery in Advanced Ovarian Cancer.

Fleming ND, Nick AM, Coleman RL, Westin SN, Ramirez PT, Soliman PT, Fellman B, Meyer LA, Schmeler KM, Lu KH, Sood AK.

Obstet Gynecol. 2018 Sep;132(3):545-554. doi: 10.1097/AOG.0000000000002796.

Supplemental Content

Loading ...
Support Center